



Notice Regarding Adjustment of 340B Prices

Anylam Pharmaceuticals, Inc. (“Anylam”), has recalculated its 340B Ceiling Prices for the period from 3Q2023 through 2Q2024 for its covered outpatient drugs due to revisions made to Average Manufacturer Prices submitted to the Centers for Medicare & Medicare Services (CMS). These restated Medicaid prices result in both upward and downward adjustments to 340B Ceiling Prices, as listed below:

Table 1: Products Subject to Upward Adjustments to the Previously Reported Ceiling Price

NDC	Product Description	340B Effective Quarter
71336-1000-01	ONPATTRO 10 MG/5 ML VIAL	3Q2023 through 2Q2024
71336-1001-01	GIVLAARI 189 MG/ML VIAL	4Q2023 through 2Q2024
71336-1002-01	OXLUMO 94.5 MG/0.5 ML VIAL	3Q2023 through 2Q2024
71336-1003-01	AMVUTTRA 25 MG/0.5 ML SYRINGE	3Q2023 through 2Q2024

Anylam has elected not to seek recoupment of these underpayments from Covered Entities.

Table 2: Products Subject to Downward Adjustments to the Previously Reported Ceiling Price

NDC	Product Description	340B Effective Quarter
71336-1001-01	GIVLAARI 189 MG/ML VIAL	3Q2023

Anylam has determined that a refund is owed to 340B Covered Entities that purchased NDC 71336100101 during the period 3Q2023. Anylam uses wholesaler chargeback records to calculate and automatically issue refund payments to impacted eligible Covered Entities at the address listed in the HRSA database.

Anylam has requested that the Health Resource and Services Administration (HRSA) post this Notice on the HRSA public website to ensure transparency to Covered Entities regarding Anylam’s recalculation and refund process. Please direct any questions and/or requests for additional information to Anylam at the following email address: ibonnemaison@alnylam.com.